|
11-11-2010, 10:47 PM
|
|||
|
|||
Press Release
Cambridge, UK, (November 11, 2010) – Amgen has announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa® (zoledronic acid) in delaying or preventing skeletal-related events (SREs) in breast cancer patients with bone metastases.
    
|
 |
| Thread Tools | |
| Display Modes | |
|
|
Linear Mode
